Literature DB >> 8844560

A controlled clinical trial for stuttering in persons aged 9 to 14 years.

A Craig1, K Hancock, E Chang, C McCready, A Shepley, A McCaul, D Costello, S Harding, R Kehren, C Masel, K Reilly.   

Abstract

This paper presents the results of a controlled trial of child stuttering treatment. The aim of the study was, first, to compare the effectiveness of three viable treatments, and, second, to compare these three treatments to a no-treatment control composed of children who stuttered of a similar age and sex ratio who were on treatment waiting lists. The three treatments investigated included intensive smooth speech, intensive electromyography feedback, and home-based smooth speech. The children/adolescents were assessed across three speaking contexts on measures of percentage syllables stuttered (% SS) and syllables spoken per minute (SPM) and outcomes were assessed 12 months later. Repeated measures analyses of variance demonstrated significant differences between the control group and all three treatment groups across time on conversations in the clinic, on the telephone, and at home (although home measures were not taken for the intensive smooth speech group). Although the controls' stuttering did not change across time, the treatment groups' stuttering was decreased to very low levels posttreatment (less than 1% syllables stuttered on average), with mean improvement in stuttering frequency of at least 85% to 90% across all assessment contexts. Stuttering did not increase significantly up to 3 months and one year posttreatment in the experimental groups, although levels did rise across time (less than 3% syllables stuttered on average). Speech naturalness results showed increasing naturalness across time as rated by the clinician and parent. This was not the case for the controls. The children were also less anxious across time following treatment. The results suggest that all three treatments for children aged 9-14 who stutter were very successful in the long term for over 70% of the group, though the EMG feedback and home-based treatments were superior when percentages falling below a cutoff point (2%SS) were used to discriminate between groups. Implications for child/adolescent treatment in the community are discussed. Long-term outcomes will be assessed up to 5 years after the treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8844560     DOI: 10.1044/jshr.3904.808

Source DB:  PubMed          Journal:  J Speech Hear Res        ISSN: 0022-4685


  7 in total

Review 1.  Stuttering: an update for physicians.

Authors:  D Costa; R Kroll
Journal:  CMAJ       Date:  2000-06-27       Impact factor: 8.262

2.  [Speech fluency disorders in childhood and adolescence].

Authors:  K Neumann
Journal:  HNO       Date:  2019-07       Impact factor: 1.284

Review 3.  Stuttering: Clinical and research update.

Authors:  Hector R Perez; James H Stoeckle
Journal:  Can Fam Physician       Date:  2016-06       Impact factor: 3.275

4.  The Pathogenesis, Assessment and Treatment of Speech Fluency Disorders.

Authors:  Katrin Neumann; Harald A Euler; Hans-Georg Bosshardt; Susanne Cook; Patricia Sandrieser; Martin Sommer
Journal:  Dtsch Arztebl Int       Date:  2017-06-05       Impact factor: 5.594

5.  Using independent component analysis to remove artifact from electroencephalographic measured during stuttered speech.

Authors:  Y Tran; A Craig; P Boord; D Craig
Journal:  Med Biol Eng Comput       Date:  2004-09       Impact factor: 2.602

6.  Using ultrasound visual feedback to remediate velar fronting in preschool children: A pilot study.

Authors:  Qiwen Heng; Patricia McCabe; Jillian Clarke; Jonathan L Preston
Journal:  Clin Linguist Phon       Date:  2016-01-25       Impact factor: 1.346

Review 7.  The state of the art in non-pharmacological interventions for developmental stuttering. Part 1: a systematic review of effectiveness.

Authors:  Susan Baxter; Maxine Johnson; Lindsay Blank; Anna Cantrell; Shelagh Brumfitt; Pam Enderby; Elizabeth Goyder
Journal:  Int J Lang Commun Disord       Date:  2015-06-30       Impact factor: 3.020

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.